

We are grateful to the patients and families who participated in Castle Creek Pharma's DELIVERS study, which evaluated the safety and efficacy of diacerein 1% ointment (CCP-020) for the treatment of Epidermolysis Bullosa Simplex (EBS). Because the Independent Data Monitoring Committee (IDMC) has indicated that the DELIVERS study, as currently designed, is unlikely to meet statistical objectives, Castle Creek has decided to discontinue the DELIVERS study.

As a next step, we plan to begin discussions with the FDA about a potential new clinical trial with an expanded number of participants.

**Important: The current study results support the safety profile of CCP-020, and patients who are currently participating in the DELIVERS study will have the option of entering an open-label safety extension trial. The results of this analysis will not impact other ongoing clinical studies for CCP-020.**

Castle Creek Pharma is dedicated to delivering transformative therapies to patients with orphan dermatologic and other underserved conditions and we remain committed to those living with Epidermolysis Bullosa.